<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362522">
  <stage>Registered</stage>
  <submitdate>21/05/2012</submitdate>
  <approvaldate>25/05/2012</approvaldate>
  <actrnumber>ACTRN12612000555853</actrnumber>
  <trial_identification>
    <studytitle>Outcome of allergen specific immunotherapy in asthmatic children</studytitle>
    <scientifictitle>Long-term clinical and immunological effect of sublingual and subcutaneous immunotherapy in dust mite allergic asthma/rhinitis children: 3 years prospective randomized controlled trial</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>childhood atopic asthma</healthcondition>
    <healthcondition>rhinitis</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Allergies</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1. sublingual immunotherapy (SLIT)+standard pharmacotherapy (SP)
patients receive SLIT as 5 sublingual droplets three times a week for 3 years (Dermatophagoides pteronyssinus and pharinea %50 mix) after following an induction phase for 1 month of slowly increasing dosing schedule reaching the maintenance dose mentioned above with the same preparation
1st dose is supervised by the physician and the rest is ingested by patient at home

2. subcutaneous immunotherapy (SCIT)+standard pharmacotherapy
SCIT is received by subcutaneous injection at the hospital by the physician once a month for 3 years (Dermatophagoides pteronyssinus and pharinea %50 mix) following a weekly injection  (for 3 months) of increasing doses of allergen.
a)starting dose of SCIT 0.1 ml of 100u/ml b) maintenance dose of SCIT 1 ml of 100000u/ml of allegen injected
every child is supervised by a physician following the injection for half an hour</interventions>
    <comparator>standard pharmacotherapy

inhaled fluticasone is administered (125 mcg) twice a day by aerospacer and puffs. Dose adjustment is made by symptom severity and disease control</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>clinical improvement by symptom severity and medication need, asthma attacks/year, pulmonary function tests, Der p 1 specific IgE levels, bronchial reactivity</outcome>
      <timepoint>baseline, 1st year, 3rd year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>immunological dynamics
peripheral blood mononuclear cells cultured wit Der P 1 (recombinant house dust mite allergen) and supernatants assayed for IL-4, 5, 13, 10, 17, TGF-b and IFN-g sscretion</outcome>
      <timepoint>baseline, 1st year, 3rd year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>to have informed consent
house dust mite sensitized
asthmatic/rhinitis child</inclusivecriteria>
    <inclusiveminage>5</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>15</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>previous immunotherapy
chronic disease
malignancy
uncontrolled asthma</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/03/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Marmara University BAPKO</primarysponsorname>
    <primarysponsoraddress>Marmara Universitesi Rektorluk Binasi
BAPKO 34722
Goztepe Istanbul</primarysponsoraddress>
    <primarysponsorcountry>Turkey</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Marmara University BAPKO</fundingname>
      <fundingaddress>Marmara Universitesi Rektorluk Binasi
BAPKO 34722
Goztepe Istanbul</fundingaddress>
      <fundingcountry>Turkey</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>randomized controlled open trial of children with mild persistant asthma, HDM sensitized were included. All evaluated at baseline 1st and 3rd years with clinical status, bronchial hyperreactivity and immunological parameters</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Marmara University Ethical Comittee</ethicname>
      <ethicaddress>Marmara Universitesi 
Tip Fakultesi Deontoloji BD
Haydarpasa 34668</ethicaddress>
      <ethicapprovaldate>28/02/2007</ethicapprovaldate>
      <hrec>30.02.FEB.0.01.02/AEK/988</hrec>
      <ethicsubmitdate>16/01/2007</ethicsubmitdate>
      <ethiccountry>Turkey</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>NewMarmara University Ethical Comittee</ethicname>
      <ethicaddress>Marmara Universitesi Tip Fakultesi Deontoloji BD Haydarpasa 34668</ethicaddress>
      <ethicapprovaldate>28/09/2010</ethicapprovaldate>
      <hrec>B.30.2.MAR.0.01.02/AEK/707</hrec>
      <ethicsubmitdate>12/03/2010</ethicsubmitdate>
      <ethiccountry>Turkey</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Elif Aydiner</name>
      <address>Marmara University Pendik EAH
Fevzi cakmak Mh Pendik Istanbul 34890</address>
      <phone>+905323517683</phone>
      <fax />
      <email>elif_karakoc@hotmail.com</email>
      <country>Turkey</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Elif Aydiner</name>
      <address>Marmara University Pendik EAH
Fevzi cakmak Mh Pendik Istanbul 34890</address>
      <phone>+905323517683</phone>
      <fax />
      <email>elif_karakoc@hotmail.com</email>
      <country>Turkey</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>